Breast Cancer Therapy Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 30.70 Billion |
| Market Size (2029) | USD 43.40 Billion |
| CAGR (2024 - 2029) | 7.17 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Breast Cancer Therapy Market Analysis
The Breast Cancer Therapy Market size is estimated at USD 30.70 billion in 2024, and is expected to reach USD 43.40 billion by 2029, growing at a CAGR of 7.17% during the forecast period (2024-2029).
The major factors fueling the market's growth are the high incidence and prevalence rates of breast cancer, increasing investment in research and development, and advancements in cancer biology and pharmacology, promoting drug development.
According to Globocan, in 2020, about 2,261,419 new cancer cases were reported worldwide, contributing to about 11.7% of the total cancer cases. As per canceraustralia.gov.au, in 2021, 20,030 new breast cancer cases were diagnosed in the country (164 males and 19,866 females). The same source reports that in 2021, a person had an estimated 1 in 15 (or 6.7%) risk of being diagnosed with breast cancer by the age of 85 (1 in 8 or 13% for females and 1 in 829 or 0.12% for males). Therefore, the high burden of breast cancer is increasing the demand for breast cancer treatment, thereby contributing to the market's growth.
The increasing focus of research studies by the market players. For instance, in September 2021, Novartis AS collaborated with Solti on HARMONIA, an international, randomized, Phase III, multicenter, and open-label study of Kisqali (ribociclib) versus Ibrance (palbociclib), both in combination with endocrine therapy. This study was on patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer with a HER2-enriched (HER2E) intrinsic subtype.
Increasing launches by manufacturers to meet the growing demand for innovative products are expected to drive market growth. For instance, in July 2021, Arvinas Inc. and Pfizer Inc. collaborated to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. Such factors potentially drive the demand for the adoption of breast cancer therapy worldwide.
On the other hand, the risk of adverse effects of radiation exposure and stringent regulatory scenarios are hindering the market's growth.
Breast Cancer Therapy Market Trends
Chemotherapy Segment Expected to Witness High Growth Over the Forecast Period
Chemotherapy is the most common form of therapy used to stop or slow down the growth of cancerous cells. It is the most common treatment for triple-negative breast cancer patients.
According to the CDC, in a November 2021 update, nearly 650,000 cancer patients (including breast cancer patients) receive chemotherapy every year in the United States. Thus, the growing number of patients receiving chemotherapy and the development of new products are expected to significantly contribute to the market's growth.
Furthermore, the number of product launches in this segment is expected to drive its growth. For instance, in July 2021, Merck, also known as MSD outside the United States and Canada, announced that the United States Food and Drug Administration (FDA) approved KEYTRUDA, Merck's anti-PD-1 therapy, for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC). Based on Phase III KEYNOTE-522 trial, this is meant to be used in combination with chemotherapy as a neoadjuvant treatment and then continued as a single agent as adjuvant treatment after surgery. Also, in May 2021, Zydus Cadila launched a next-generation breast cancer drug in India. The drug, Trastuzumab emtasine, is considered the first targeted chemotherapy drug for breast cancer.
Thus, owing to the abovementioned factors, the market segment is expected to show growth over the forecast period.
North America Expected to Dominate the Market Over the Forecast Period
Within North America, the United States is expected to dominate the overall market throughout the forecast period. The major factors fueling the market's growth are the increasing burden of breast cancer in the country, growing awareness about breast cancer, and increasing product launches.
In the United States, breast cancer is one of the leading cancer types. According to the January 2022 update by breastcancer.org, around 1 in 8 women in the country (about 13%) develop invasive breast cancer over their lifetime. The same source reports that, in 2022, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the United States, as well as 51,400 new cases of non-invasive (in situ) breast cancer. As per the same source, about 2,710 new cases of invasive breast cancer are expected to be diagnosed in men in 2022. A man's lifetime risk of breast cancer is about 1 in 833.
Furthermore, as per an October 2021 update by the University of North Carolina's School of Medicine, Susan G. Komen, the world's leading breast cancer organization, announced that it would award USD 1.5 million for three new research projects that examine three unique areas focused on metastatic breast cancer (MBC).
In April 2021, Gilead Sciences Inc. reported that the US FDA granted full approval to Trodelvy (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. Thus the increased product approval from the US FDA is expected to boost the growth of the market over the forecast period.
Thus, due to the above-mentioned factors, the market in North America is expected to grow during the forecast period.
Breast Cancer Therapy Industry Overview
The breast cancer therapy market is competitive and consists of several major and small players. Some of the major players in the market are Novartis AG, Pfizer Inc., F. Hoffmann-La Roche, Eisai Co. Ltd., and Merck & Co. Inc.
Breast Cancer Therapy Market Leaders
-
Novartis AG
-
Merck Co & Inc.
-
Fresenius Kabi
-
Pfizer Inc.
-
Eli Lilly & Co.
*Disclaimer: Major Players sorted in no particular order
Breast Cancer Therapy Market News
- In September 2022, Novartis announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program, confirming nearly one year of additional overall survival (OS) benefit in a subgroup of patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer (aBC).
- In August 2022, the United States Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with unresectable (unable to be removed) or metastatic (spread to other parts of the body) HER2-low breast cancer. This is one of the first approved therapies targeted to patients with the HER2-low breast cancer subtype, which is a newly defined subset of HER2-negative breast cancer.
Breast Cancer Therapy Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Incidence and Prevalence Rate of Breast Cancer
4.2.2 Increasing Investments in R&D
4.2.3 Advancements in Cancer Biology and Pharmacology, Promoting Drug Development
4.3 Market Restraints
4.3.1 Risk of Adverse Effects of Radiation Exposure
4.3.2 Stringent Regulatory Scenarios
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Therapy
5.1.1 Radiation Therapy
5.1.2 Targeted Therapy
5.1.2.1 Herceptin
5.1.2.2 Tykerb (Lapatinib)
5.1.2.3 Afinitor
5.1.2.4 Other Targeted Therapies
5.1.3 Hormonal Therapy
5.1.3.1 Selective Estrogen - Receptor Modulators
5.1.3.2 Aromatase Inhibitors
5.1.3.3 Other Hormonal Therapies
5.1.4 Chemotherapy
5.1.4.1 Taxanes
5.1.4.2 Anthracyclines
5.1.4.3 Anti-metabolites
5.1.4.4 Alkylating Agents
5.1.4.5 Epothilones
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AstraZeneca PLC
6.1.2 Bristol-Myers Squibb Company
6.1.3 Eisai Co. Ltd
6.1.4 Eli Lilly and Company
6.1.5 Genentech
6.1.6 GlaxoSmithKline PLC
6.1.7 Halozyme Inc.
6.1.8 Novartis AG
6.1.9 Pfizer Inc.
6.1.10 Hikma Pharmaceuticals
6.1.11 Baxter Healthcare Corporation
6.1.12 FRESENIUS KABI
6.1.13 Teva Pharmaceutical Industries Ltd
6.1.14 Celltrion Healthcare
6.1.15 Viatris Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Breast Cancer Therapy Industry Segmentation
As per the scope of this report, breast cancer therapy refers to cancer treatment with chemotherapy, targeted therapy, hormonal therapy, etc. These therapies block the growth and proliferation of cancer by interfering with specific molecules, such as DNA or proteins, that are involved in the growth or expansion of cancerous cells. The breast cancer therapy market is segmented by therapy (radiation therapy, targeted therapy, hormonal therapy, and chemotherapy) and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the market sizes and forecasts in terms of value (USD million) for the above segments.
| By Therapy | |||||||
| Radiation Therapy | |||||||
| |||||||
| |||||||
|
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Breast Cancer Therapy Market Research FAQs
How big is the Breast Cancer Therapy Market?
The Breast Cancer Therapy Market size is expected to reach USD 30.70 billion in 2024 and grow at a CAGR of 7.17% to reach USD 43.40 billion by 2029.
What is the current Breast Cancer Therapy Market size?
In 2024, the Breast Cancer Therapy Market size is expected to reach USD 30.70 billion.
Who are the key players in Breast Cancer Therapy Market?
Novartis AG, Merck Co & Inc., Fresenius Kabi, Pfizer Inc. and Eli Lilly & Co. are the major companies operating in the Breast Cancer Therapy Market.
Which is the fastest growing region in Breast Cancer Therapy Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Breast Cancer Therapy Market?
In 2024, the North America accounts for the largest market share in Breast Cancer Therapy Market.
What years does this Breast Cancer Therapy Market cover, and what was the market size in 2023?
In 2023, the Breast Cancer Therapy Market size was estimated at USD 28.50 billion. The report covers the Breast Cancer Therapy Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Breast Cancer Therapy Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Breast Cancer Therapy Industry Report
Statistics for the 2024 Breast Cancer Therapy market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Breast Cancer Therapy analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
